Opportunity
Quebec SEAO #INSPQ-10741-24C
Human EDTA Whole Blood and Serum for INSPQ Laboratory Activities
Posted
October 30, 2026
Respond By
November 14, 2026
Identifier
INSPQ-10741-24C
NAICS
621991, 325414, 424210
The Institut national de santé publique du Québec (INSPQ), through its Centre de toxicologie du Québec (CTQ), seeks a reliable supply of human biological matrices for laboratory work. - Buyer: INSPQ, through the Centre de toxicologie du Québec (CTQ). - Intended supplier / OEM: BioIVT. - Products requested: - Human whole blood anticoagulated with EDTA. - Human serum. - Ordering and packaging: On-demand orders of 1–10 litres per matrix per order, supplied in individual 1-litre containers. Total quantities are based on actual requirements; no part numbers are specified. - Key requirements: Documented collection, processing, storage, and distribution procedures; lot traceability; controlled cold-chain handling; and required viral testing. INSPQ may perform preliminary analytical checks on delivered lots. - Use: Interlaboratory control materials, analytical method development and validation, and specialized analytical work. - Procurement context: INSPQ intends to negotiate a sole-source supply contract with BioIVT. Businesses may submit documented evidence that equivalent products meet the technical requirements and are compatible with CTQ analytical methods.
Description
The Institut national de santé publique du Québec intends to negotiate a sole-source, on-demand supply contract with BioIVT for human whole blood anticoagulated with EDTA and human serum. The matrices will support interlaboratory control materials, analytical method development and validation, and specialized analytical activities at the Centre de toxicologie du Québec. Supplies must meet stated requirements for documented procedures, lot traceability, controlled cold chain, and viral testing, and must be delivered in individual one-litre containers; orders may range from a minimum of one litre to up to 10 litres per matrix. The planned contract duration is five years, with a planned conclusion date of November 19, 2026; businesses may submit documented expressions of interest demonstrating equivalent products.